Algipharma AS
Not financial advice. The index, rank, signals and advice are rule-based indications from the latest filed annual accounts. They are not a credit rating, an assessment of management or a recommendation to buy, sell or do business with the company. Read more
Score · fiscal year 2025
Not enough data: Not enough data (below minimum revenue)
Based on the annual accounts for 2025
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 0 MNOK | 2 MNOK |
| Operating margin | −23,016.6% | 7.8% |
| Profit margin | −29,696.3% | 7.8% |
| Return on assets | −2.2% | 14.1% |
| Equity ratio | 84.8% | 43.1% |
| Debt-to-equity | 0.18 | 1.04 |
| Current ratio | 0.51 | 1.71 |
| Revenue growth | 409.2% | 6.9% |
| Revenue per employee | 0.00 MNOK | 0.85 MNOK |
The median and “ahead of” refer to companies in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
Score over time
Score over time needs at least two fiscal years with a score. It will appear when next year's figures are fetched or history is imported.
Working capital and debt
| Measure | Company | Median | |
|---|---|---|---|
| Working capital | |||
| Receivable days All current receivables, including those on group companies, in days of revenue. |
75,538 days | 44 days | |
| Inventory and other current assets, days Current assets other than receivables and bank deposits, that is inventory and short-term investments, in days of revenue. |
0 days | 0 days | |
| Net working capital to revenue Current assets less bank deposits less current liabilities, divided by revenue. Negative: short-term debt funds the operations. |
−31,226.2% | −7.1% | |
| Cash share of current assets How much of the short-term buffer is bank deposits and cash. |
21.7% | 57.8% | |
| Debt and interest burden | |||
| Interest coverage (times) Operating result divided by all financial costs. Below 1: operations do not cover the cost of the debt. |
−1.9 | 14.9 | |
| Financial costs as a share of debt All financial costs (interest, currency losses and other) divided by all debt, interest-free debt included. Not an interest rate. |
10.1% | 0.6% | |
| Long-term share of debt Long-term debt as a share of all debt. A low share means more falls due within a year. |
57.1% | 2.3% | |
The operating result is negative, so the interest coverage is negative: operations cover none of the financial costs.
Net working capital (current assets less bank deposits less current liabilities): −9.1 MNOK.
Of the financial costs of 3.6 MNOK, 2.2 MNOK is reported as interest costs in the accounts.
The median and the bar refer to companies in the same sector in 2025. The bar shows the share of the group with a lower figure: higher is not always better, long receivable days tie up capital, for example. These figures do not count in the score.
The industry or the company: what drove the result?
In 2025 the operating margin of Algipharma AS rose by 96,509.9 percentage points. Comparable companies fell by a median 0.2 points. So the company did 96,510.1 points better than the industry, for reasons of its own.
Over 2 year-to-year changes Algipharma AS moved the same way as comparable companies 1 times. About 0% of the changes in operating margin were common to the industry; the rest was the company's own.
| Year | The company | Comparable (median) | Change, company | Change, industry | The company's own |
|---|---|---|---|---|---|
| 2024 | −119,526.4% | 8.0% | −112,726.7 percentage points | −0.5 percentage points | −112,726.2 percentage points |
| 2025 | −23,016.6% | 7.8% | +96,509.9 percentage points | −0.2 percentage points | +96,510.1 percentage points |
Comparable companies are those in the same industry and Morning company class. Their change shows what hit the whole industry, the sector drivers below included. The rest is the company's own: contracts, costs, one-off items or operations. The share is approximate, and we claim no cause.
The company and its sector's drivers
Prices, rate and currency that shape the sector's year, year by year beside the operating margin of Algipharma AS. The figures stand side by side; we claim no cause.
Turnover index: architectural and engineering activities (indeks (2021 = 100))
Turnover index: architectural and engineering activities rose 8.1% in 2025; the operating margin of Algipharma AS rose 96,509.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Turnover index: architectural and engineering activities, annual average | 99.0 | 108.8 | 127.9 | 146.4 | 158.3 | 155.2 (so far) |
| Change from the year before | +9.8% | +9.9% | +17.5% | +14.5% | +8.1% | −1.9% |
| The company's operating margin | – | – | −6,799.7% | −119,526.4% | −23,016.6% | – |
Source: SSB (13863, CC BY 4.0). Source
Turnover index: advertising and market research (indeks (2021 = 100))
Turnover index: advertising and market research rose 3.6% in 2025; the operating margin of Algipharma AS rose 96,509.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Turnover index: advertising and market research, annual average | 99.4 | 113.5 | 108.3 | 106.9 | 110.7 | 126.1 (so far) |
| Change from the year before | +35.1% | +14.2% | −4.6% | −1.3% | +3.6% | +13.9% |
| The company's operating margin | – | – | −6,799.7% | −119,526.4% | −23,016.6% | – |
Source: SSB (13863, CC BY 4.0). Source
Turnover index: other professional and technical activities (indeks (2021 = 100))
Turnover index: other professional and technical activities rose 6.2% in 2025; the operating margin of Algipharma AS rose 96,509.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Turnover index: other professional and technical activities, annual average | 98.3 | 121.6 | 139.4 | 131.0 | 139.1 | 158.0 (so far) |
| Change from the year before | +29.9% | +23.7% | +14.6% | −6.0% | +6.2% | +13.6% |
| The company's operating margin | – | – | −6,799.7% | −119,526.4% | −23,016.6% | – |
Source: SSB (13863, CC BY 4.0). Source
Service prices: architects and engineering (indeks (2021 = 100))
Service prices: architects and engineering rose 3.2% in 2025; the operating margin of Algipharma AS rose 96,509.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Service prices: architects and engineering, annual average | 100.0 | 103.6 | 107.5 | 111.2 | 114.7 | 119.4 (so far) |
| Change from the year before | +1.2% | +3.5% | +3.8% | +3.4% | +3.2% | +4.2% |
| The company's operating margin | – | – | −6,799.7% | −119,526.4% | −23,016.6% | – |
Source: SSB (14335, CC BY 4.0). Source
Oil price (export price of crude oil) (kr per fat)
Oil price (export price of crude oil) fell 17.6% in 2025; the operating margin of Algipharma AS rose 96,509.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Oil price (export price of crude oil), annual average | 609 | 979 | 877 | 859 | 708 | 881 (so far) |
| Change from the year before | +61.1% | +60.8% | −10.5% | −2.0% | −17.6% | +24.5% |
| The company's operating margin | – | – | −6,799.7% | −119,526.4% | −23,016.6% | – |
Source: SSB (08799, CC BY 4.0). Source
Policy rate (prosent)
Policy rate fell 0.20 percentage points in 2025; the operating margin of Algipharma AS rose 96,509.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Policy rate, annual average | 0.08 | 1.32 | 3.54 | 4.50 | 4.30 | 4.17 (so far) |
| Change from the year before | −0.28 percentage points | +1.24 percentage points | +2.22 percentage points | +0.96 percentage points | −0.20 percentage points | −0.12 percentage points |
| The company's operating margin | – | – | −6,799.7% | −119,526.4% | −23,016.6% | – |
Source: Norges Bank (IR, NLOD 2.0). Source
EUR/NOK (kr)
EUR/NOK rose 0.8% in 2025; the operating margin of Algipharma AS rose 96,509.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| EUR/NOK, annual average | 10.16 | 10.10 | 11.42 | 11.62 | 11.72 | 11.04 (so far) |
| Change from the year before | −5.2% | −0.6% | +13.1% | +1.8% | +0.8% | −5.8% |
| The company's operating margin | – | – | −6,799.7% | −119,526.4% | −23,016.6% | – |
Source: Norges Bank (EXR, NLOD 2.0). Source
Wage index: architects and engineering (indeks)
Wage index: architects and engineering rose 4.7% in 2025; the operating margin of Algipharma AS rose 96,509.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Wage index: architects and engineering, annual average | 90.5 | 90.9 | 96.0 | 100.9 | 105.6 | 109.2 (so far) |
| Change from the year before | +7.4% | +0.5% | +5.6% | +5.2% | +4.7% | +3.4% |
| The company's operating margin | – | – | −6,799.7% | −119,526.4% | −23,016.6% | – |
Source: SSB (12314, CC BY 4.0). Source
We show the drivers and the margin side by side and claim no cause. Sensitivity per company is not computed until we have at least 10 years of accounts per company: with three years such figures are false precision.
What the numbers say
Algipharma AS had an equity ratio of 84.8% in 2025. The company is not ranked: not enough data (below minimum revenue).
From 2024 to 2025: the operating margin rose from −119,526.4% to −23,016.6% and revenue grew by 409%.
This text is generated automatically from the 2025 accounts.
Three simple methods
One method gives a figure: 481 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 18.6 | not meaningful |
| EV/EBIT | 15.9 | not meaningful |
| P/B | 3.2 | 481 MNOK |
The listed basis is the value at listed multiples. The estimate is lowered for size: a small-company premium of 2% on the cost of equity gives a value 24% lower. No separate marketability discount is applied, because the premium already allows for the company being small and unlisted.
The NACE code has no listed industry of its own in the table, so the multiples are the sector median: Engineering/Construction, Business & Consumer Services.
Not financial advice. The value range is a rough model estimate from listed-company multiples, not a valuation, a price target or a price offer. The actual value may differ greatly. Read more
A mechanical estimate from public accounts, not advice. A mechanical estimate from public accounts with listed multiples and fixed adjustments. Not a valuation and not advice to buy or sell. See the calculation
Worth a closer look
- critical
The operating result does not cover the financial costs. How will the debt be serviced, and what do the lenders say?
Based on: Interest coverage (times) −1.9 (median 14.9); Financial costs as a share of debt 10.1% (median 0.6%).
- watch
Consider strengthening liquidity: current liabilities are 2.0 times current assets.
Based on: Current ratio 0.51 (median 1.71).
- watch
The company made a loss before tax. Are these one-off items or a pattern?
Based on: Profit margin −29,696.3% (median 7.8%).
- watch
The operating margin is lower than at three in four companies in the sector. Where do costs differ from competitors?
Based on: Operating margin −23,016.6% (median 7.8%).
- watch
Strong growth with weak liquidity. Is the growth financed, or does it tie up capital the company does not have?
Based on: Revenue growth 409.2% (median 6.9%); Current ratio 0.51 (median 1.71).
- watch
Receivables equal far more days of revenue than at comparable companies. Do customers pay late, or are these loans to companies in the same group?
Based on: Receivable days 75,538 days (median 44 days).
- watch
Current liabilities exceed current assets other than bank deposits, and the current ratio is weak. Is it customer prepayments and supplier credit that fund the operations, or short-term loans that must be renewed?
Based on: Net working capital to revenue −31,226.2% (median −7.1%); Current ratio 0.51 (median 1.71).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 10.1% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
- watch Extreme margin: check the figures
Scenario analysis: the sector's weakest year
We have no accounts for 2021, the sector's weakest year, for this company.
The sector's weakest year was 2021, with a median operating margin of −0.2%. Based on the 10 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
Questions and answers
How profitable is Algipharma AS?
The operating margin was −23,016.6% in 2025, against a median of 7.8% among companies in the same sector. Return on assets was −2.2%. The company made a loss before tax.
How solid is Algipharma AS?
The equity ratio was 84.8% in 2025 (median 43.1%). Debt-to-equity was 0.18 (median 1.04).
What is the liquidity of Algipharma AS like?
The current ratio was 0.51 in 2025 (median 1.71). Current assets did not cover current liabilities.
Group structure · 2025
7 companies in the group according to the shareholder register for 2025. A company counts as a subsidiary when a Norwegian company owns more than half of its shares.
Private persons own 100% of the shares in Frydenberg AS. Persons are not shown by name.
Frydenberg AS has not filed group accounts in open data, so the group has no index of its own. Each company has its own accounts.
The group in figures
- Sectors
- Industri (5 companies), Teknisk tjenesteyting og forskning (2 companies) 7 of 7 companies in the tree have accounts with us. Sectors are sorted by the companies' own revenue, which includes sales between the group's companies.
- Employees in Norway
- 18 in all. Drammen 12, Bærum 6 Registered employees in the Central Coordinating Register, by the municipality of the business address. Employees may work elsewhere.
- Loss
- 2 companies: Algipharma AS, Algipharma Holding AS
A subsidiary with negative equity or a loss may be backed by the group, for example with group contributions or guarantees. It is an indication of what is worth asking about, not an assessment.
-
Frydenberg AS
-
Drammen Slip & Verksted AS
-
Algipharma Holding AS
- Algipharma AS you are here
-
-
Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.
Source: the Norwegian Tax Administration's shareholder register 2025 (majority owner with more than 50 % of the shares). Voting agreements and ownership through other countries are not included.
From the Central Coordinating Register
- Org. no.
- 964911444
- Legal form
- AS
- Sector
- Teknisk tjenesteyting og forskning (72.100)
- Morning company class
- Micro
- Employees
- 6 registered 10 July 2024
- Founded
- 25 May 1992 34 years in operation
- Share capital
- 2.82 MNOK
- Business address
- Industriveien 33, 1337 SANDVIKA (BÆRUM)
- Municipality
- Bærum rank 1 of 11 in KOSTRA group 12
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
Loading roles …
Source: Central Coordinating Register, fetched 1 November 2026. Only names are shown.
Shareholders (2025)
- Number of shareholders
- 1 (one owner)
- Largest owner
- 100.0%
- Split
- companies 100% · private persons 0% · foreign 0%
- Owned from the same municipality
- 100%
- Group chain
-
Owned by: Algipharma Holding AS (100%)
Ultimate owner: private person
The owner: the majority owner Algipharma Holding AS (holds 100%) made a loss in 2025. A weak parent can affect the subsidiary through group contributions, loans and guarantees. It is an indication to watch, not an assessment of the company.
- Algipharma Holding AS · 100.0%
Change 2007–2025:
100% of the shares changed owner (1 new and 3 departed owners). The majority owner changed.
New owners (companies): Algipharma Holding AS
Departed (companies): DRAMMEN SLIP & Verksted AS, Roquette Norway AS, STIFTELSEN BIOPOLYMER
Source: the Norwegian Tax Administration's shareholder register as of 2025. Figures may be older than today's ownership. Private persons are not shown by name.
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Is this your company? Suggest changes or add information
Figures last fetched 8 November 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | – | – | – | |
| Rank | – | – | – | |
| Operating margin | −6,799.7% | −119,526.4% | −23,016.6% | |
| Return on assets | −2.1% | −2.5% | −2.2% | |
| Equity ratio | 68.1% | 85.0% | 84.8% | |
| Current ratio | 0.58 | 0.35 | 0.51 | |
| Revenue growth | – | −93.3% | 409.2% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 0.1 MNOK | 0.0 MNOK | 0.0 MNOK |
| Operating profit | −5.8 MNOK | −6.9 MNOK | −6.7 MNOK |
| Profit before tax | −9.8 MNOK | −9.0 MNOK | −8.7 MNOK |
| Tax expense | −0.1 MNOK | 0.0 MNOK | 0.0 MNOK |
| Net profit | −9.7 MNOK | −9.0 MNOK | −8.7 MNOK |
| Financial expenses | 5.9 MNOK | 3.8 MNOK | 3.6 MNOK |
| Total assets | 188.9 MNOK | 207.3 MNOK | 232.8 MNOK |
| Current assets | 7.3 MNOK | 5.8 MNOK | 7.7 MNOK |
| Equity | 128.6 MNOK | 176.1 MNOK | 197.5 MNOK |
| Retained earnings | – | – | – |
| Total liabilities | 60.3 MNOK | 31.2 MNOK | 35.4 MNOK |
| Current liabilities | 12.6 MNOK | 16.4 MNOK | 15.2 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 8 November 2026, accounts id 7100998.